ARTICLE | Finance
Bear out of Hibernation
Euthymics Bioscience gets $24M from VCs to revive CNS assets from Dov PharmaFrench plays Cerenis, Trophos and Novagali boost VC fortunes
July 26, 2010 7:00 AM UTC
Dov Pharmaceutical Inc. has been slowing dying for a long time, but its neglected assets are now back in play in newco Euthymics Bioscience Inc., which VCs financed with $24 million in a tranched series A round last week.
At the same time, Euthymics completed its merger into Dov, which was announced in February, but taking it private instead of keeping the public listing...